Shareholder Meeting Results
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): October
27, 2006
AEOLUS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
0-50481 56-1953785
(Commission
File Number)
(IRS
Employer Identification No.)
23811
Inverness Place
Laguna
Niguel, California 92677
(Address
of Principal Executive Offices, Including Zip Code)
949-481-9825
(Registrant’s
Telephone Number, Including Area Code)
__________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| £ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| £ |
Soliiting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| £ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
| £ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.03 Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
October 27, 2006, the shareholders of Aeolus Pharmaceuticals, Inc. approved
an
Amendment of the Amended and Restated Certificate of Incorporation to increase
the authorized number of shares of Common Stock from ten million (10,000,000)
shares to one hundred fifty million (150,000,000) shares.
A
copy of
the Certificate of Amendment of Amended and Restated Certificate of
Incorporation is attached as Exhibit 3.1 to this Current Report on Form
8-K.
Item
9.01. Financial Statements and Exhibits.
|
Exhibit
#
|
|
Description
|
|
3.1
|
|
Certificate
of Amendment of Amended and Restated Certificate of
Incorporation
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
AEOLUS
PHARMACEUTICALS, INC.
Date:
October 30, 2006
/s/
Michael P. McManus___________________
Michael
P. McManus
Chief
Financial Officer, Treasurer and Secretary